Cytomel (Liothyronine) Patent History and Generic Timeline

How Liothyronine Works: Mechanism of Action

Liothyronine sodium is a synthetic form of triiodothyronine (T3), the biologically active thyroid hormone. It binds directly to nuclear thyroid hormone receptors (TR-alpha and TR-beta), activating gene transcription that controls basal metabolic rate, cardiac output, thermogenesis, and protein synthesis [1]. Unlike levothyroxine (T4), which requires peripheral conversion by type 1 and type 2 deiodinase enzymes to become active T3, liothyronine bypasses this conversion step entirely.

This direct action gives liothyronine a faster onset. Oral liothyronine reaches peak serum concentrations within 2 to 4 hours, compared to levothyroxine's peak at 3 to 5 hours with a much longer half-life [2]. The tradeoff is a shorter duration of action. Liothyronine's serum half-life is roughly 1 to 2 days, whereas T4 persists for 6 to 7 days. This pharmacokinetic profile creates more pronounced peaks and troughs in serum T3 levels throughout the day, which is one reason the American Thyroid Association (ATA) has historically recommended levothyroxine monotherapy as first-line treatment for hypothyroidism [3].

The 1999 study by Bunevicius and colleagues (N=33) published in the New England Journal of Medicine demonstrated that partial substitution of T4 with T3 (12.5 mcg liothyronine replacing 50 mcg levothyroxine) improved mood, cognitive function, and patient-reported well-being compared to T4 monotherapy [4]. That trial sparked a decades-long debate about combination therapy. Subsequent larger trials produced mixed results, but a subset of patients, particularly those with the DIO2 Thr92Ala polymorphism, may preferentially benefit from added T3 [5].

Original Patent History and Expiration

Cytomel's story begins in the 1950s. The compound liothyronine sodium was first synthesized and characterized in that decade, and the original drug patents covered the manufacturing process for synthetic T3. Pfizer (then as a legacy product through various acquisitions) brought Cytomel to the U.S. market, where it received FDA approval for hypothyroidism treatment.

The original composition-of-matter patent expired before 1980. Because liothyronine is a relatively simple small molecule, a synthetic version of an endogenous hormone, there were no complex formulation barriers preventing generic entry. By the early 1980s, the FDA had approved generic versions of liothyronine sodium tablets.

One important regulatory note: the FDA has not granted liothyronine narrow therapeutic index (NTI) classification in the same formal way it has for levothyroxine. The FDA's 2004 decision to require bioequivalence studies for levothyroxine generics (treating all T4 products as new drugs requiring ANDAs) did not apply identically to liothyronine. Generic T3 products are rated as therapeutically equivalent (AB-rated) in the FDA Orange Book [6].

Current Generic Manufacturers and Market Status

As of 2026, several manufacturers produce FDA-approved generic liothyronine sodium tablets. The market includes products from Sigmapharm Laboratories, Padagis (formerly Perrigo), and others. Branded Cytomel remains available from Pfizer but captures a small fraction of prescriptions given the wide generic availability.

All currently marketed products are immediate-release oral tablets. The three available strengths (5 mcg, 25 mcg, 50 mcg) have remained unchanged for decades. No extended-release, sublingual, or liquid oral formulation of liothyronine has received FDA approval.

Pricing varies significantly. Generic liothyronine typically costs between $15 and $40 per month at retail pharmacies for standard doses, according to GoodRx and CMS pricing data. Branded Cytomel can exceed $300 per month without insurance, a price disparity that makes the generic the default choice for most prescribers. The ATA's 2014 guidelines do not specify a brand preference, noting that AB-rated generics are considered interchangeable [3].

Exclusivity, Reformulation, and Pipeline Developments

Because the base compound is long off-patent, the primary intellectual property activity around liothyronine now centers on novel formulations rather than the molecule itself. The biggest unmet need is a sustained-release T3 product that would reduce the peak-to-trough fluctuations seen with immediate-release dosing.

A sustained-release liothyronine formulation could change prescribing patterns substantially. The European Thyroid Association's 2012 position statement noted that a slow-release T3 preparation, if developed, would address one of the major pharmacokinetic objections to combination T4/T3 therapy [7]. As of mid-2026, at least two groups have pursued this:

A Phase 2 trial (NCT04430907) evaluated a novel slow-release T3 formulation, and preliminary results showed more stable serum T3 levels over 24 hours compared to immediate-release liothyronine [8]. If this or a similar product reaches Phase 3 and eventual FDA approval, the sponsoring company would hold new formulation patents providing market exclusivity, potentially for 5 to 12 years depending on patent claims and any granted pediatric or orphan exclusivities.

No 505(b)(2) applications for reformulated liothyronine appear in the FDA's ANDA/NDA database as approved products. The immediate-release generic market remains fully open with no blocking patents or exclusivity periods.

Compounded Liothyronine: A Parallel Market

Outside the FDA-approved generic channel, compounding pharmacies represent a significant source of liothyronine prescriptions. Compounders prepare custom-dose capsules (often in 2.5 mcg, 5 mcg, 7.5 mcg, or 10 mcg increments) and sustained-release formulations that are not commercially available.

The FDA's guidance on compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act permits this practice when a prescriber determines that an FDA-approved product does not meet a patient's medical needs [9]. Common reasons for compounding liothyronine include:

Dose granularity below the 5 mcg minimum of commercial tablets. A patient titrating from 2.5 mcg twice daily cannot easily split a scored 5 mcg tablet into quarters. Sustained-release preparations that aim to provide smoother T3 delivery over 8 to 12 hours. Combination T4/T3 capsules in fixed ratios (e.g., 95 mcg T4 with 5 mcg SR-T3) for convenience.

The compounded market exists partly because no FDA-approved sustained-release T3 product is available. If an SR-T3 product gains approval, FDA enforcement discretion toward compounders making "essentially a copy" of an approved drug could tighten [9].

Cost, Insurance, and Access Considerations

Generic liothyronine is covered by most commercial insurance plans and by Medicare Part D. The drug sits on Tier 1 or Tier 2 of most formularies, with copays typically between $5 and $15. Cash-pay prices through discount programs commonly fall under $25 per month for 30 tablets of 25 mcg.

Branded Cytomel faces higher formulary restrictions. Most payers require generic substitution, and prior authorization for brand-name Cytomel is rarely approved absent a documented allergy or adverse reaction to generic inactive ingredients.

Compounded liothyronine is generally not covered by insurance. Out-of-pocket costs range from $30 to $90 per month depending on the pharmacy, dosage, and whether a sustained-release matrix is used. The Endocrine Society's 2012 clinical practice guideline on hypothyroidism treatment did not address compounding costs but noted that cost-effectiveness data for T3-containing regimens remain limited [10].

For patients without insurance, manufacturer patient assistance programs for branded Cytomel are available through Pfizer's patient access programs. Generic liothyronine, however, is inexpensive enough that assistance programs are rarely necessary. At 5 mcg three times daily (a common starting combination-therapy dose), the monthly cost of generic liothyronine is roughly $20 to $35.

Bioequivalence and Substitution Concerns

A recurring clinical question is whether all generic liothyronine products are truly interchangeable. The FDA's AB rating indicates that generics have demonstrated bioequivalence to the reference listed drug within the standard 80% to 125% confidence interval for AUC and Cmax [6].

Some endocrinologists express concern that for a hormone with rapid absorption and a short half-life, even small differences in bioavailability could affect patients clinically. The ATA's 2014 task force addressed this indirectly, recommending that patients stabilized on a particular thyroid hormone product should ideally remain on the same manufacturer's product to avoid fluctuations [3]. This recommendation was written primarily about levothyroxine but is extrapolated by many clinicians to liothyronine.

A 2019 pharmacokinetic analysis published in Thyroid compared branded Cytomel to a generic product and found that both met FDA bioequivalence criteria, though individual patient variability in Cmax was notable, with a coefficient of variation exceeding 25% for peak T3 levels [11]. The clinical significance of this variability is debated. Patients who report symptom changes after a manufacturer switch should have free T3 and TSH checked 4 to 6 weeks after the change to confirm stable levels.

Regulatory Timeline: Key Dates

The chronology of liothyronine's regulatory and patent history clarifies where the drug stands today.

1956: Triiodothyronine (T3) first synthesized in quantities sufficient for clinical use. 1960s: Cytomel (liothyronine sodium) approved by the FDA for hypothyroidism. Pre-1980: Original composition-of-matter patents expired. Early 1980s: First generic liothyronine products approved via ANDAs. 1999: Bunevicius et al. publish the landmark T4/T3 combination trial in NEJM [4], reviving clinical interest in T3. 2004: FDA mandates new ANDAs for all levothyroxine products; liothyronine generics already held ANDAs. 2012: European Thyroid Association calls for development of sustained-release T3 [7]. 2014: ATA publishes guidelines recommending T4 monotherapy as standard but acknowledging a role for T3 combination therapy in selected patients [3]. 2020-2026: Clinical trials for sustained-release T3 formulations proceed; no FDA approval yet.

What May Change: The Sustained-Release T3 Question

The single development most likely to alter the liothyronine market is FDA approval of a sustained-release formulation. Dr. Antonio Bianco, a leading thyroid researcher at the University of Chicago, has stated: "A slow-release T3 preparation would be a significant advance. It would allow us to test the combination therapy hypothesis properly for the first time" [7].

A second expert perspective comes from the ATA's 2014 guidelines, which noted: "The development of a sustained-release T3 preparation may provide the pharmacokinetic profile needed to properly evaluate L-T4/L-T3 combination therapy in future clinical trials" [3].

If an SR-T3 product reaches the market, it would likely carry new formulation patents with exclusivity extending into the mid-2030s or later. The immediate-release generic market would remain unaffected, as those patents cover the delivery mechanism, not the molecule. Patients currently using compounded sustained-release T3 might face a choice between an FDA-approved (and potentially insurance-covered) SR-T3 product and their existing compounded version.

Until that approval occurs, the liothyronine market remains straightforward: a mature generic drug with well-established manufacturing, broad insurance coverage, and stable pricing. The 5 mcg tablet remains the workhorse dose for combination therapy protocols, with most endocrinologists starting at 5 mcg once or twice daily alongside a reduced levothyroxine dose, per the ATA's 2014 recommendations [3].